Numerate Forms Drug Discovery Collaboration with Merck & Co., Inc. (MRK) to Utilize Numerate’s In Silico Drug Design Technology
3/14/2012 8:36:14 AM
SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that it has entered into a research collaboration with Merck, through a subsidiary. The collaboration will utilize Numerate’s proprietary in silico drug design technology to generate novel small molecule drug leads for an undisclosed cardiovascular disease target.
comments powered by